EADV 2022: Lebrikizumab Efficacious in Moderate-to-Severe Atopic Dermatitis
16-week results demonstrate favorable response versus placebo as assessed by IGA, EASI-75, and Pruritus NRS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.